Drugs / 15-Valent Pneumococcal Conjugate Vaccine

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04108845 Jun 2019 → Aug 2020 streptococcal pneumonia Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Unknown No outcome recorded
Phase 32 trials
Phase 3 NCT06817187 Sep 2021 → Mar 2024 pneumococcal infection Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Completed No outcome recorded
Phase 3 NCT04357522 Jul 2020 → Mar 2026 streptococcal pneumonia Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Unknown No outcome recorded
Phase not applicable1 trial
NCT05939219 Jul 2023 → Jan 2025 Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06524414 Comparator Jul 2024 → May 2027 expected pneumococcal infection Pfizer Active not recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as 15-valent pneumococcal conjugate vaccine 15-valent pneumococcal conjugate vaccineNCT06817187
5

NCT06524414

NCT05939219

NCT04357522

NCT06817187

NCT04108845

Modality Vaccine “15-Valent Pneumococcal Conjugate VaccineNCT04108845
Route Intramuscular “Single intramuscular dose” NCT04108845